Mount Sinai Health System spinoff Sema4 has achieved a valuation of more than $1bn following a $121m series C round that featured all existing external shareholders.
Sema4, a US-based health information spinoff from integrated health system Mount Sinai Health System, yesterday raised $121m in a series C round led by investment management company BlackRock.
Deerfield Management Company, Moore Strategic Ventures, Blackstone, Section 32, Oak HC/FT, Decheng Capital and Connecticut Innovations also took part in the round, which valued Sema4 at more than $1bn post-money.
Sema4 provides screening services to help diagnose, treat and prevent disease. The company initially focused on producing models for reproductive health but has since added precision oncology and Covid-19 to its capabilities.
Andrew Elbardissi, a partner at Deerfield, has joined Sema4’s board of directors.
The company was formed by Mount Sinai in 2017 with a “substantial investment” from the health system. Its technology was developed within Mount Sinai’s private education college, Icahn School of Medicine.
Blackstone, Section 32, Oak HC/FT, Decheng Capital and Connecticut Innovations provided $120m in series B funding in August 2019.
